Bas van de Kar

598 total citations
10 papers, 462 citations indexed

About

Bas van de Kar is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Bas van de Kar has authored 10 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Genetics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Bas van de Kar's work include Chronic Lymphocytic Leukemia Research (6 papers), Melanoma and MAPK Pathways (3 papers) and Synthesis and biological activity (2 papers). Bas van de Kar is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Melanoma and MAPK Pathways (3 papers) and Synthesis and biological activity (2 papers). Bas van de Kar collaborates with scholars based in Netherlands, United States and Switzerland. Bas van de Kar's co-authors include Tjeerd Barf, Allard Kaptein, Michael Gulrajani, Todd Covey, Dennis Demont, Diana Mittag, Edwin de Zwart, Bart van Lith, Fanny Krantz and Raquel Izumi and has published in prestigious journals such as Blood, Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Bas van de Kar

10 papers receiving 451 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bas van de Kar Netherlands	8	325	240	150	129	90	10	462
Dennis Demont Netherlands	6	280 0.9×	206 0.9×	187 1.2×	109 0.8×	80 0.9×	8	490
Bart van Lith United States	7	319 1.0×	240 1.0×	105 0.7×	131 1.0×	87 1.0×	8	406
Edwin de Zwart United States	6	252 0.8×	191 0.8×	104 0.7×	106 0.8×	70 0.8×	7	356
Fanny Krantz United States	7	401 1.2×	300 1.3×	129 0.9×	147 1.1×	128 1.4×	12	495
Swaroop Vakkalanka United States	11	266 0.8×	244 1.0×	210 1.4×	72 0.6×	131 1.5×	46	551
Lesley Liu‐Bujalski United States	7	192 0.6×	104 0.4×	146 1.0×	70 0.5×	98 1.1×	10	346
Christina Liu United States	7	147 0.5×	133 0.6×	240 1.6×	53 0.4×	45 0.5×	14	465
Wendy B. Young United States	8	100 0.3×	44 0.2×	70 0.5×	93 0.7×	56 0.6×	13	297
Jin Shu China	9	89 0.3×	86 0.4×	111 0.7×	64 0.5×	52 0.6×	18	285
Kwee Hyun Suh South Korea	9	78 0.2×	48 0.2×	141 0.9×	39 0.3×	45 0.5×	32	341

Countries citing papers authored by Bas van de Kar

Since Specialization

Citations

This map shows the geographic impact of Bas van de Kar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bas van de Kar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bas van de Kar more than expected).

Fields of papers citing papers by Bas van de Kar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bas van de Kar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bas van de Kar. The network helps show where Bas van de Kar may publish in the future.

Co-authorship network of co-authors of Bas van de Kar

This figure shows the co-authorship network connecting the top 25 collaborators of Bas van de Kar. A scholar is included among the top collaborators of Bas van de Kar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bas van de Kar. Bas van de Kar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Demont, Dennis, et al.. (2021). Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors. Bioorganic & Medicinal Chemistry Letters. 52. 128406–128406. 2 indexed citations

Bruin, Gerjan de, Dennis Demont, Edwin de Zwart, et al.. (2020). Discovery of quinoline-based irreversible BTK inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(14). 127261–127261. 7 indexed citations

Kaptein, Allard, Gerjan de Bruin, Bas van de Kar, et al.. (2019). Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 19. S316–S317. 1 indexed citations

Kaptein, Allard, Gerjan de Bruin, Bas van de Kar, et al.. (2018). Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Blood. 132(Supplement 1). 1871–1871. 71 indexed citations

Barf, Tjeerd, Todd Covey, Raquel Izumi, et al.. (2017). Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Journal of Pharmacology and Experimental Therapeutics. 363(2). 240–252. 272 indexed citations

Covey, Todd, Tjeerd Barf, Michael Gulrajani, et al.. (2015). Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Research. 75(15_Supplement). 2596–2596. 36 indexed citations

Hoogendoorn, Sascha, Bas van de Kar, Allard Kaptein, et al.. (2015). Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Organic & Biomolecular Chemistry. 13(18). 5147–5157. 24 indexed citations

Barf, Tjeerd, Allard Kaptein, Dennis Demont, et al.. (2011). Structure-based lead identification of ATP-competitive MK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(12). 3818–3822. 19 indexed citations

Oubrie, Arthur, Allard Kaptein, Edwin de Zwart, et al.. (2011). Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Bioorganic & Medicinal Chemistry Letters. 22(1). 613–618. 13 indexed citations

10.

Kaptein, Allard, Arthur Oubrie, Edwin de Zwart, et al.. (2011). Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(12). 3823–3827. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact